Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02528409 · ClinicalTrials.gov registry record · Phase 2
Vortioxetine for Binge Eating Disorder
A Phase 2 study of Binge-Eating Disorder, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02528409 is a Phase 2 study of Binge-Eating Disorder that has completed, run by University of Chicago. The registered enrollment target is 80 participants, below the 1,141-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02528409, a Phase 2 study of Binge-Eating Disorder, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vortioxetine
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02528409
The ClinicalTrials.gov registry entry for NCT02528409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (93% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02528409 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02528409 about?
NCT02528409 is a clinical study titled "Vortioxetine for Binge Eating Disorder". The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.
What is the current status of trial NCT02528409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-06. Estimated completion is 2018-11-01.
What conditions does trial NCT02528409 study?
This clinical trial studies the following conditions: Binge-Eating Disorder.
What interventions are being tested in trial NCT02528409?
The interventions under investigation include: Placebo (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02528409?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02528409 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
RECRUITING · Phase 2
-
A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
RECRUITING · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
COMPLETED · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
COMPLETED · Phase 2
-
Dasotraline Binge Eating Disorder Study
COMPLETED · Phase 2
-
Craving, Binge Eating and Obesity
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.